CN114042124A - Traditional Chinese medicine preparation for treating pulmonary vitreous nodules and preparation method and application thereof - Google Patents
Traditional Chinese medicine preparation for treating pulmonary vitreous nodules and preparation method and application thereof Download PDFInfo
- Publication number
- CN114042124A CN114042124A CN202111453321.3A CN202111453321A CN114042124A CN 114042124 A CN114042124 A CN 114042124A CN 202111453321 A CN202111453321 A CN 202111453321A CN 114042124 A CN114042124 A CN 114042124A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- nodules
- traditional chinese
- lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Insects & Arthropods (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine preparation for treating pulmonary vitreous nodules, which belongs to the field of traditional Chinese medicines and is prepared from the following raw materials in parts by weight: 6-9 parts of edible tulip, 3-9 parts of spina gleditsiae, 20-40 parts of selfheal, 6-9 parts of uniflower swisscentaury root, 20-40 parts of astragalus membranaceus, 10-20 parts of radix pseudostellariae, 5-15 parts of scutellaria baicalensis, 4-8 parts of pericarpium citri reticulatae, 5-15 parts of rhizoma pinellinae praeparata, 5-15 parts of cowherb seed, 5-15 parts of fried honeycomb, 3-6 parts of scorpion and 3-10 parts of taxus chinensis.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine preparation for treating pulmonary vitreous nodules, and a preparation method and application thereof.
Background
In recent years, with the widespread use of chest CT examination in health examination, the probability of finding lung nodules is significantly increased, and the detectable lung nodules have smaller and smaller diameters. The Ground Glass Nodules (GGN) of the lung are light and thin cloud-like rounded nodules with slightly increased density found on thin-layer CT examination of the chest, named for their morphology similar to ground glass, and can grow focally or diffusely. Research shows that GGN has higher malignancy rate and larger correlation with early lung cancer compared with solid nodules. According to the latest multidisciplinary classification, lung adenocarcinomas are classified according to the degree of infiltration into Atypical Adenomatous Hyperplasia (AAH), carcinoma in situ (AIS), microaneurturized adenocarcinoma (MIA) and Invasive Adenocarcinoma (IAC), all four types of which can be shown as GGN in CT. In addition, for patients with a history of malignant tumors (especially a history of lung cancer), a short-term progressive increase of nodules and a high risk of obvious CT signs, the potential risk of lung cancer transformation from the lung frosted nodules is significantly higher than that of common people. Aiming at the latest cancer data published by the international cancer research institution of the world health organization in 2020, the lung cancer is still the first malignant tumor of Chinese morbidity and mortality, and the GGN is used as an early manifestation form of the lung cancer, and has important significance for reducing the occurrence of the lung cancer and relieving the bad emotion of a patient by carrying out drug intervention on the lung cancer.
The treatment strategy of modern medicine for the pulmonary vitreous nodules is mainly regular follow-up visit, biopsy and surgical treatment if necessary. Biopsy, as an invasive procedure, can affect lung function to some extent, and for smaller lesions there may be cases where detection difficulties lead to missed diagnosis, or the risk of tumor implantation in the biopsy channel. For treatment by surgical resection of the nodules, on one hand, postoperative complications such as decreased lung function, postoperative local adhesion inflammation, intractable cough and the like can occur; on the other hand, since the internal environment responsible for the formation of pulmonary nodules is not improved, multiple pulmonary nodules still appear after surgery, however, multiple surgeries are not tolerated by most patients.
In conclusion, the modern medicine lacks effective treatment medicines for the disease at present and has no clear effective medicine treatment method. In the mechanism of pulmonary nodules, the lung is considered to be the delicate organ, which is located at the upper part and is easily invaded by exogenous pathogens. Because a large amount of pollutants, such as harmful substances produced by tobacco, exhaust emission and cooking fume of food, exist in the existing living environment, which are dry heat, soak in the orifices of the lung, cause abnormal distribution of body fluids, phlegm accumulation and heat accumulation, and lung failure in dispersing and descending; the lung fails to disperse and descend, and phlegm-heat will flow out without way, forming a tangible node and obstructing the airway. Therefore, the treatment is essential for dredging lung orifice to clear phlegm stagnation, and then clearing and nourishing lung qi to promote toxin expelling, so as to expel pathogen and tonify the lung while expelling the lung qi. Therefore, the method creates a prescription for the treatment and is widely applied to clinical treatment, and the clinical curative effect which is satisfied by the patient can be achieved. In prospective one-armed clinical studies, it was found that in 125 patients with complete imaging data before and after treatment, lung nodules were not developed in all patients, nodules of some patients were withdrawn, and nodules of some patients were completely disappeared. Meanwhile, none of the patients experienced discomfort symptoms. The inventor shows that the inventor creatively combines the effects of dredging and dispersing, and treating both the deficiency and the tonification in one prescription, has strict and exquisite prescription and safe and effective clinic, so that the inventor needs to apply for a patent and deeply research the prescription to benefit more patients.
Disclosure of Invention
The purpose of the invention is as follows: the invention aims to provide a medicament for treating pulmonary vitreous nodules, which has the advantages of obvious curative effect, good safety, low treatment cost and convenient administration, by theoretical innovation, therapeutic innovation, medicament selection and strict composition under the guidance of basic theories of traditional Chinese medicine aiming at pulmonary vitreous nodule symptoms displayed by patient imaging.
The technical scheme is as follows: the purpose of the invention is realized by the following scheme:
a traditional Chinese medicine preparation for treating pulmonary vitreous nodules is prepared from the following raw materials in parts by weight: 6-9 parts of edible tulip, 3-9 parts of spina gleditsiae, 20-40 parts of selfheal, 6-9 parts of uniflower swisscentaury root, 20-40 parts of astragalus membranaceus, 10-20 parts of radix pseudostellariae, 5-15 parts of scutellaria baicalensis, 4-8 parts of pericarpium citri reticulatae, 5-15 parts of rhizoma pinellinae praeparata, 5-15 parts of cowherb seed, 5-15 parts of fried honeycomb, 3-6 parts of scorpion and 3-10 parts of taxus chinensis.
The traditional Chinese medicine preparation for treating pulmonary vitreous nodules is prepared from the following raw materials in parts by weight: 9 parts of edible tulip, 9 parts of spina gleditsiae, 30 parts of selfheal, 9 parts of uniflower swisscentaury root, 30 parts of astragalus membranaceus, 15 parts of radix pseudostellariae, 10 parts of scutellaria baicalensis, 6 parts of dried orange peel, 10 parts of rhizoma pinellinae praeparata, 10 parts of cowherb seed, 10 parts of fried honeycomb, 5 parts of scorpion and 5 parts of taxus chinensis.
The preparation method of the traditional Chinese medicine preparation for treating pulmonary vitreous nodules comprises the following steps:
(1) soaking the above materials in water for 30 min, decocting for 2 times, adding water 10-12 times the weight of the materials for the first time, decocting for 20-25 min, taking out the decoction after the decoction is finished, adding water 8-10 times the weight of the materials into the residues, decocting for 15-20 min, taking out the decoction, mixing the decoctions, concentrating, adding adjuvants, and making into liquid or solid preparation.
(2) The liquid preparation is one of decoction and mixture, and the solid preparation is one of tablet, capsule and granule.
The traditional Chinese medicine preparation for treating pulmonary vitreous tubercle is applied to preparation of medicines for treating pulmonary vitreous tubercle.
The using method comprises the following steps: the medicine is taken in the morning and evening, 3 months are 1 course of treatment, and at least 2 courses of treatment are recommended.
Among the above drugs, wherein:
and (3) edible tulip: the product is pseudobulb of Rhododendron simsii Roxb and Pleiones bulbocodioides of Orchidaceae. Sweet, slightly pungent and cold in nature; it enters liver and spleen meridians. Has the functions of detumescence, resolving masses, reducing phlegm and detoxifying. It is indicated for abscess, deep-rooted carbuncle, furuncle, scrofula, sore throat, snake, worm and mad dog injuries.
Spina gleditsiae: the product is dried thorn of Gleditsia sinensis Lam. Pungent taste and warm nature; it enters liver and stomach meridians. Has the functions of eliminating swelling, expelling toxin, discharging pus and killing pests. Can be used for treating early carbuncle and cellulitis or suppurative abscess; it is indicated for external treatment of scabies and leprosy.
Selfheal: the product is dried fruit cluster of Prunella vulgaris L. of Labiatae. Pungent, bitter and cold in nature; it enters liver and gallbladder meridians. Has the effects of clearing away fire, improving eyesight, dispersing pathogenic accumulation, and relieving swelling. Can be used for treating conjunctival congestion, swelling and pain, eyeball nyctalgia, headache, giddiness, scrofula, goiter, mammary abscess, and swelling and pain; goiter, tuberculous lymphadenitis, hyperplasia of mammary glands, and hypertension.
And (4) uniflower swisscentaury root: the product is dried root of Rhaponticum uniflorum (L.) DC. of Compositae. Bitter taste and cold nature; it enters stomach meridian. Has effects of clearing away heat and toxic materials, eliminating carbuncle, promoting lactation, relaxing muscles and tendons, and dredging collaterals. Can be used for treating acute mastitis, swelling and pain, carbuncle, cellulitis, sore, scrofula, breast milk obstruction, and spasm due to damp arthralgia.
Astragalus root: the product is dried root of Astragalus membranaceus (Fisch.) Bge. of Leguminosae family or Astragalus membranaceus (Fisch.) Bge. Hsiao. Sweet taste and warm nature; it enters lung and spleen meridians. Has effects in invigorating qi, consolidating exterior, promoting urination, expelling toxin, expelling pus, healing sore, and promoting granulation. Can be used for treating deficiency of vital energy, asthenia, anorexia, loose stool, collapse of middle-warmer energy, chronic diarrhea, rectocele, hematochezia, metrorrhagia, superficial deficiency, spontaneous perspiration, qi deficiency, edema, carbuncle, cellulitis, intractable ulcer, blood deficiency, debility with yellowish complexion, internal heat, and diabetes; proteinuria due to chronic nephritis and diabetes.
Radix pseudostellariae: the product is root tuber of Pseudostellaria heterophylla (Miq.) Pax ex Paxet Hoffm. Sweet, slightly bitter and neutral in nature; it enters spleen and lung meridians. Has effects of invigorating qi, invigorating spleen, promoting fluid production, and moistening lung. Can be used for treating spleen deficiency, asthenia, deficiency of qi and yin, spontaneous perspiration, thirst, and dry cough due to lung noise.
Scutellaria baicalensis: the product is dried root of Scutellaria baicalensis Georgi of Labiatae. Bitter taste and cold nature; it enters lung, gallbladder, spleen, large intestine and small intestine meridians. Has the functions of clearing away heat, eliminating dampness, purging fire, detoxicating, stopping bleeding and preventing miscarriage. Can be used for treating chest distress, nausea, damp-heat, dysentery, jaundice, cough due to lung heat, hyperpyrexia, polydipsia, hematemesis, carbuncle, swelling, sore, and threatened abortion.
Seed of cowherb: is seed of Vaccinium arvense of Caryophyllaceae. Bitter taste and mild nature; it enters liver and stomach meridians. Has the effects of promoting blood circulation, stimulating menstrual flow, inducing lactation, reducing swelling and healing sore. Can be used for treating amenorrhea, galactostasis, dystocia, stranguria with blood, carbuncle, swelling, and bleeding due to incised wound.
Dried orange peel: the product is dry mature pericarp of Citrus reticulata Blanco of Rutaceae and its cultivar. The medicinal materials are classified into pericarpium citri reticulatae and pericarpium citri reticulatae. Bitter, pungent and warm in nature; it enters lung and spleen meridians. Has the effects of regulating qi, strengthening spleen, eliminating dampness and phlegm. Can be used for treating fullness in chest and abdomen, anorexia, vomiting, diarrhea, cough, and excessive phlegm.
Rhizoma pinelliae preparata: the product is processed product of rhizoma Pinelliae. Pungent taste and warm nature; it enters spleen, stomach and lung meridians. Has effects of eliminating dampness and phlegm. Can be used for treating cough and asthma due to excessive phlegm, dizziness and palpitation due to phlegm and fluid retention, dizziness due to wind-phlegm, phlegm syncope and headache.
And (3) honeycomb frying: the product is nest of Vespidae insect Polistes olivacea (DeGeer), Polistes japonica baussure or Parapelya varia Fabricius. Sweet in taste and neutral in nature; it enters stomach meridian. Has the effects of dispelling pathogenic wind, removing toxic substances, killing parasite, and relieving pain. Can be used for treating toothache due to dental caries, pyocutaneous disease, toxic swelling, mammary abscess, scrofula, and intractable tinea.
Scorpion: the product is dried body of Buthus martensii Karsch belonging to family Buthidae. Pungent, neutral and toxic; it enters liver meridian. Has the effects of calming endogenous wind, relieving spasm, counteracting toxic pathogen, resolving hard mass, dredging collaterals, and relieving pain. Can be used for treating infantile convulsion, spasm, facial distortion due to apoplexy, hemiplegia, tetanus, rheumatism, headache, pyocutaneous disease, and lymphoid tuberculosis.
Chinese yew: the product is prepared from Taxus chinensis var mairei (Taxus chinensis, Taxaceae) Cheng et L.K.Fu (T.speciosa Florin) by seed selection. Has effects in promoting digestion, killing parasite, relieving diarrhea, stopping bleeding, and resisting cancer. It is used for treating food stagnation and ascariasis. Meanwhile, modern researches show that the taxus chinensis has anticancer effect because branches, leaves, wood and seeds of the taxus chinensis generally contain taxol with antitumor activity.
Has the advantages that:
1. condensation core pathogenesis: no clear disease name corresponding to 'lung grinding glass nodule' exists in the traditional theory of traditional Chinese medicine. Most patients have no typical clinical manifestations, and the core pathogenesis of 'phlegm coagulation and heat accumulation and lung deficiency and collateral obstruction' of lung-milled vitreous nodules is innovatively proposed according to the etiology and pathogenesis characteristics of tumor formation and the pathological features of lung diseases.
2. Innovation of therapeutic principles and therapeutic methods: proposes the treatment idea that lung nodules should be removed and passed through to help support and eliminate pathogens from collaterals. According to the lung stagnation disease mechanism, the treatment needs to dredge the lung orifice to clear phlegm stagnation, then clear and nourish lung qi to promote toxin expelling, and the treatment needs to be one-way, support tonifying and expel pathogenic factors. The treatment method of resolving phlegm and dissipating nodulation, benefiting lung and expelling toxin is to hit the pathogenesis.
3. Meticulous prescription composition: combines clinical evidence experience, centers on the prescription of treatment rules, has clear prescription, is monarch, minister, assistant and guide, and is matched with meticulous treatment, combined dredging and dispersing, and the clearing and tonifying are treated simultaneously. The monarch drugs in the invention are edible tulip and spina gleditsiae. The edible tulip can dissipate stagnation and reduce phlegm, and clear away heat and toxic materials; spina Gleditsiae has toxic materials clearing away and pus discharge promoting effects; the two drugs are used together to clear phlegm, remove pathogenic toxin and expel pathogenic factors from collaterals. The ministerial drugs comprise Prunellae Spica, radix Rhapontici, radix astragali, and radix Pseudostellariae. The selfheal can clear heat and dissipate stagnation to help clear and dissipate; radix Rhapontici has the effects of dredging collaterals and resolving carbuncle to promote pathogenic factors to flow out of collaterals, so that the pathogenic factors flow out of the collaterals; radix astragali and radix Pseudostellariae have the effects of tonifying lung, nourishing yin, and consolidating constitution to help expel toxin. Radix Scutellariae, pericarpium Citri Reticulatae, rhizoma Pinelliae Preparatum, semen Vaccariae, nidus Vespae, Scolopendra, and ramulus et folium taxi Cuspidatae. The scutellaria baicalensis clears away the lung-heat and detoxifies; pericarpium Citri Tangerinae and rhizoma Pinelliae Preparata for eliminating dampness and phlegm; the cowherb seed promotes blood circulation and dredges the menstrual flow; nidus Vespae and Scorpio have effects of dredging collaterals and removing toxic substance; the yew detoxifies and resists cancer; the seven medicines are used together as adjuvant drugs. The medicines have the effects of clearing away phlegm and eliminating stagnation, benefiting lung and expelling toxin together so as to eliminate the lung stagnation and expel pathogenic factors from collaterals.
4. The curative effect is definite: the prospective single-arm clinical research is adopted, and the conclusion is real and objective according to clinical data. The number of the nodules of 125 patients is 9, 7.20% and the number of the nodules of 43 patients with retraction is 34.40% after treatment; 73 stable nodules, 58.40%; nodules were 0 cases ineffective, accounting for 0%. The final statistical result shows that the effective rate of the prescription for treating the pulmonary abrasion vitreous tubercle is 100%.
5. Safety and convenience are achieved: the formula is widely applied clinically, patients can use the formula for 3 years at most, no adverse reaction and toxic or side effect occur, and the safety is good; meanwhile, the invention is an oral preparation, is simple to use, is pleasant to be accepted by patients and can be used for a long time.
Detailed Description
The foregoing aspects of the present invention are described in further detail below by way of examples, but it should not be construed that the scope of the above-described subject matter of the present invention is limited to the following examples, and that all the technologies implemented based on the above-described aspects of the present invention are within the scope of the present invention.
Example 1: taking 9 g of edible tulip, 9 g of spina gleditsiae, 20 g of selfheal, 9 g of uniflower swisscentaury root, 20 g of astragalus root, 20 g of radix pseudostellariae, 5 g of scutellaria baicalensis, 8 g of dried orange peel, 5 g of rhizoma pinellinae praeparata, 15 g of cowherb seed, 5 g of fried honeycomb, 6 g of scorpion and g of taxus chinensis, soaking the raw materials in water for 30 minutes, decocting for 2 times, adding water in an amount which is 12 times of the weight of the medicines for the first time, decocting for 25 minutes, taking out decoction after the decoction is finished, adding water in an amount which is 10 times of the weight of the medicines into dregs, decocting for 20 minutes twice, taking out the decoction, combining the decoction obtained in two times, and preparing the decoction. The using method comprises the following steps: the preparation is administered 1 dose per day in the morning and evening, 3 months is 1 treatment course, and at least 2 treatment courses are recommended.
Example 2: taking 9 g of edible tulip, 5 g of spina gleditsiae, 40 g of selfheal, 9 g of uniflower swisscentaury root, 40 g of astragalus root, 10 g of radix pseudostellariae, 15 g of scutellaria baicalensis, 4 g of dried orange peel, 15 g of rhizoma pinellinae praeparata, 5 g of cowherb seed, 15 g of fried honeycomb, 3 g of scorpion and 8 g of taxus chinensis, soaking the raw materials in water for 30 minutes, decocting for 2 times, adding water 10 times of the weight of the medicine for the first time, decocting for 20 minutes, taking out decoction after the decoction is finished, adding 8 times of water of the weight of medicine into dregs, decocting for 15 minutes, taking out the decoction, combining the decoction obtained in two times, concentrating, adding starch, and preparing into granules.
Example 3: taking 9 g of edible tulip, 6 g of spina gleditsiae, 30 g of selfheal, 9 g of uniflower swisscentaury root, 30 g of astragalus root, 15 g of radix pseudostellariae, 10 g of scutellaria baicalensis, 6 g of dried orange peel, 10 g of rhizoma pinellinae praeparata, 10 g of cowherb seed, 10 g of fried honeycomb, 5 g of scorpion and 5 g of taxus chinensis, soaking the raw materials in water for 30 minutes, decocting for 2 times, adding water 12 times of the weight of the medicine for the first time, decocting for 25 minutes, taking out decoction after the decoction is finished, adding water 10 times of the weight of medicine into dregs, decocting for 20 minutes, taking out the decoction, combining the two decoctions, concentrating, adding dextrin, and preparing the capsule.
Example 4: clinical study on pulmonary vitreous nodules treated by the invention
1. Study type: prospective one-armed study
2. Clinical data: from 10 months to 11 months in 2018, 125 lung-milled glass nodule cases with age of 32-83 years, mean age (57.9 +/-12.1), 81 women accounting for 65% and 44 men accounting for 35% in outpatient service of oncology department of traditional Chinese medicine department of Jiangsu province, which meet case selection criteria, in 2018.
3. Diagnosis standard (refer to 2018 edition Chinese expert consensus for diagnosis and treatment of pulmonary nodules): the imaging is characterized by focal, roundish-like, and solid or hyposolid lung shadows with increased density with a diameter less than or equal to 3cm, which can be isolated or multiple, and are not accompanied by atelectasis, pulmonal lymphadenectasis, and pleural effusion.
4. Inclusion criteria were:
(1) patients who meet the diagnosis standard of pulmonary nodules and have the maximum diameter of the pulmonary vitreous nodules of more than or equal to 0.3 cm;
(2) the age is 18-85 years old, and the nature is not limited.
5. Exclusion criteria:
(1) examining the patients with maximum diameter of lung grinding glass nodule smaller than 0.3cm by pulmonary nodule imaging;
(2) other sites originate from lung metastatic nodules of malignant tumors.
(3) Those with severe primary heart, liver, lung, kidney, blood or severe disease affecting their survival.
(4) Disabled patients as prescribed by law (blind, deaf, dumb, intellectual disability, mental disorder, physical disability).
(5) Suspected or definite history of alcohol, drug abuse.
(6) According to the judgment of researchers, other pathological changes which reduce the possibility of group entry or complicate the group entry are caused, such as the condition that the working environment is frequently changed and the like, which easily causes missed visits.
(7) Allergic constitution, e.g. a history of allergy to two or more drugs or food; or known to be allergic to the present drug component.
6. The treatment scheme comprises the following steps:
the Chinese medicinal preparation is used for treating patients with confirmed diagnosis, 1 dose is prepared according to the compatibility formula every day, the prepared decoction is uniformly taken twice, 1 time is taken in the morning and at night, 1 treatment course is taken in 3 months, and at least 2 treatment courses are recommended.
7. The evaluation standard of curative effect is as follows:
and (3) curing: the pulmonary nodule imaging examination returns to normal or the target focus disappears;
retraction: the number of pulmonary nodule imaging examinations is reduced or the maximum diameter is reduced compared with the front;
and (3) stabilizing: the pulmonary nodule imaging examination is similar to the previous one;
and (4) invalidation: the number of pulmonary nodule imaging examinations increases more or the maximum diameter increases more than before.
8. The treatment results are as follows:
the number of the nodules of 125 patients is 9, 7.20% and the number of the nodules of 43 patients with retraction is 34.40% after treatment; 73 stable nodules, 58.40%; nodules were 0 cases ineffective, accounting for 0%. The total improvement rate is 41.60 percent, and the total effective rate is 100 percent.
Wherein, the medicine is taken for less than 1 month, the patients are rechecked for 11 people, the improvement rate is 36.36 percent, and the effective rate is 100 percent. Wherein 1 patient with stable nodule disappears after continuing to take the traditional Chinese medicine for 6 months.
The patients are rechecked for 16 patients after taking the medicine for 1 month, the improvement rate is 25.00 percent, and the effective rate is 100 percent.
The patients are rechecked for 29 patients after taking the medicine for 2 months, the improvement rate is 31.03 percent, and the effective rate is 100 percent. Wherein 1 patient with stable nodule continuously takes Chinese medicine for 6 months to improve the nodule.
The patients are rechecked for 63 patients after taking the medicine for 3 months, the improvement rate is 36.51 percent, and the effective rate is 100 percent. Wherein the nodules of 2 patients with stable nodules are improved after continuously taking the traditional Chinese medicine for 3 months, and the nodules of the other 1 patients with stable nodules disappear after continuously taking the traditional Chinese medicine for 3 months.
The patients are rechecked for 52 patients after taking the medicine for 6 months, the improvement rate is 46.15 percent, and the effective rate is 100 percent. Wherein 1 nodule patient disappears after taking the traditional Chinese medicine for 6 months.
Finally, the effective rate of the prescription for treating the pulmonary abrasion vitreous tubercle is 100 percent. (see Table 1 for details).
Table 1: curative effect of traditional Chinese medicine for treating pulmonary nodules
The improvement rate is 100% (the number of cured people + the number of regressions)/the total number of people, and the effective rate is 100% (the number of cured people + the number of regressions + the number of stable people)/the total number of people.
9. And (4) conclusion:
the clinical research shows that none of the patients who are observed shows nodule development, and 41.60 percent of the patients with nodule regression and disappearance show that the traditional Chinese medicine composition is effective in treating pulmonary vitreous nodules and has a trend of rising curative effect along with the prolonging of the medication time. Meanwhile, the invention has good safety, has no adverse effect on the functions of bone marrow, liver and kidney and gastrointestinal tract, can be taken for a long time and brings continuous benefit to patients. The invention is innovation in the medicine for treating pulmonary abrasion vitreous nodule, and has remarkable economic and social benefits.
10. Typical cases are:
case 1
Wang A in a male, age 44, Han nationality. 2020-03 in the field of radical lung cancer treatment, 2020-07-09 in the reexamination of chest CT suggests that two lungs have a plurality of small solid and ground glass nodules, the larger one is located in the anterior basal segment of the right inferior lobe of the right lung, which is a mixed ground glass nodule, and the maximum diameter is about 5 mm. 2021-07-23, the treatment comes before, the treatment is as follows: paroxysmal cough with frequent white and sticky sputum accompanied by little cough, no hoarseness and no obvious discomfort.
The above materials are decocted 1 dose a day, and taken in the morning and evening. 2020-09-07 review chest CT cues: compared with 2020-07-09 front ground glass nodules are not seen.
Case 2
Jin in, woman, age 52, han nationality. 2021-05 radical lung cancer therapy at the periphery, 2021-08-07 reexamination of chest CT shows the lower right lobe mill glass density shadow (IMG15) with a diameter of about 7 mm. 2021-08-26 the patients are diagnosed before, and the surgical site is complained of obvious traction feeling, anorexia, no obvious cough, expectoration, chest distress, short breath and hoarseness. .
The above materials are decocted 1 dose a day, and taken in the morning and evening. 2021-11-02 review chest CT cues: the density of the ground glass on the right inferior lung lobe is not seen in this time.
Case 3
Somebody in grandson, female, 65 years old, Han nationality. In 2019, in the field of hospital, lung cancer radical treatment, and in 2020-03-02 rows after operation, breast CT shows solid nodules of the left lung inferior lobe (IMG41), which are about 8mm in size, rough in edge, small nodules of the left lung inferior lobe, 5mm in diameter, and multiple-milled glass nodules of two lungs, and the larger diameter is about 0.6 cm. The doctor visits the rear 2020-04-20 before, and the doctor visits the doctor: chest distress and short breath, especially after activities, and relieved after rest, without cough, expectoration, hoarseness and other symptoms.
The above materials are decocted 1 dose a day, and taken in the morning and evening. 2020-06-01 Breast CT review prompt: the node of the original left inferior lung lobe (IMG41), which is not seen this time.
Case 4
Hou certain, woman, age 45, Han nationality. 2021-07-12 chest CT indications in my hospital row: the anterior inner basal segment of the inferior lobe of the left lung is seen as a mixed ground glass nodule (Img231), the maximum diameter is about 11cm, and suspicious stenosis of a running bronchiole can be seen in the mixed ground glass nodule; the rest two lungs can see a plurality of small nodule shadows with milled glass density, the larger one is located on the upper tongue section of the upper lobe of the left lung and is a pure milled glass nodule (Img150), and the maximum diameter is about 7 mm. 2021-07-12, the treatment comes before, the treatment is as follows: only CT in the chest indicates abnormality, and has no obvious clinical symptoms of cough, expectoration, hoarseness, chest distress, short breath and the like.
The above materials are decocted 1 dose a day, and taken in the morning and evening. 2021-11-18 review chest CT cues: the larger nodes of the anterior inner basal segment of the inferior lobe of the left lung, which are shown in the front panel, are not seen in this time.
Case 5
Chen somebody, male, 37 years old, Han nationality. Row 2020-08-23 chest CT shows two lungs with multiple nodules, the larger located in the basal segment of the left lung inferior lobe, with a frosted glass density and a maximum diameter of about 5.3 mm. The doctor visits 2020-09-28 before, and the doctor visits: patients who need adrenocortical adenoma operation in traditional Chinese medicine hospital in 8 months in 2020 have the symptoms of unconsciousness, weakness, earlier decline of exercise tolerance, no cough, expectoration, chest distress, short breath, hoarseness and the like. The above materials are decocted 1 dose a day, and taken in the morning and evening. 2020-12-17 review chest CT cues: when comparing 2020-08-03 tablets, the original inferior lobe mill vitreous nodules of the left lung disappeared.
Claims (4)
1. The traditional Chinese medicine preparation for treating pulmonary vitreous nodules is characterized by being prepared from the following raw materials in parts by weight: 6-9 parts of edible tulip, 3-9 parts of spina gleditsiae, 20-40 parts of selfheal, 6-9 parts of uniflower swisscentaury root, 20-40 parts of astragalus membranaceus, 10-20 parts of radix pseudostellariae, 5-15 parts of scutellaria baicalensis, 4-8 parts of pericarpium citri reticulatae, 5-15 parts of rhizoma pinellinae praeparata, 5-15 parts of cowherb seed, 5-15 parts of fried honeycomb, 3-6 parts of scorpion and 3-8 parts of taxus chinensis.
2. The traditional Chinese medicine preparation for treating pulmonary vitreous tubercle according to claim 1, which is prepared from the following raw materials in parts by weight: 9 parts of edible tulip, 9 parts of spina gleditsiae, 30 parts of selfheal, 9 parts of uniflower swisscentaury root, 30 parts of astragalus membranaceus, 15 parts of radix pseudostellariae, 10 parts of scutellaria baicalensis, 6 parts of dried orange peel, 10 parts of rhizoma pinellinae praeparata, 10 parts of cowherb seed, 10 parts of fried honeycomb, 5 parts of scorpion and 5 parts of taxus chinensis.
3. The traditional Chinese medicine preparation for treating pulmonary vitreous tubercle according to claim 1, wherein the preparation method comprises the following steps:
(1) soaking the above materials in water for 30 min, decocting for 2 times, adding water 10-12 times the weight of the materials for the first time, decocting for 20-25 min, taking out the decoction after the decoction is finished, adding water 8-10 times the weight of the materials into the residues, decocting for 15-20 min, taking out the decoction, mixing the decoctions, concentrating, adding adjuvants, and making into liquid or solid preparation.
(2) The liquid preparation is one of decoction and mixture, and the solid preparation is one of tablet, capsule and granule.
4. The use of the Chinese medicinal preparation for treating pulmonary vitreous tubercle of claim 1 in the preparation of a medicament for treating pulmonary vitreous tubercle.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111453321.3A CN114042124B (en) | 2021-12-01 | 2021-12-01 | Traditional Chinese medicine preparation for treating pulmonary vitreous nodules and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111453321.3A CN114042124B (en) | 2021-12-01 | 2021-12-01 | Traditional Chinese medicine preparation for treating pulmonary vitreous nodules and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114042124A true CN114042124A (en) | 2022-02-15 |
CN114042124B CN114042124B (en) | 2022-10-28 |
Family
ID=80211864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111453321.3A Active CN114042124B (en) | 2021-12-01 | 2021-12-01 | Traditional Chinese medicine preparation for treating pulmonary vitreous nodules and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114042124B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115737769A (en) * | 2022-11-24 | 2023-03-07 | 周国莉 | A suit of dosing for treating pulmonary nodule |
CN116211982A (en) * | 2023-01-17 | 2023-06-06 | 上海市普陀区中心医院 | Compound preparation for treating middle-low-risk pulmonary nodules, preparation method and application |
CN116920066A (en) * | 2023-09-09 | 2023-10-24 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | Traditional Chinese medicine composition for treating lung nodules and lung cancer as well as preparation and application thereof |
CN117244015A (en) * | 2023-09-12 | 2023-12-19 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | Traditional Chinese medicine composition for treating pulmonary nodules and application thereof |
-
2021
- 2021-12-01 CN CN202111453321.3A patent/CN114042124B/en active Active
Non-Patent Citations (1)
Title |
---|
陶劲等: ""罗玲从‘虚’与‘气滞痰瘀’论治肺结节"", 《结直肠***外科》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115737769A (en) * | 2022-11-24 | 2023-03-07 | 周国莉 | A suit of dosing for treating pulmonary nodule |
CN116211982A (en) * | 2023-01-17 | 2023-06-06 | 上海市普陀区中心医院 | Compound preparation for treating middle-low-risk pulmonary nodules, preparation method and application |
CN116211982B (en) * | 2023-01-17 | 2023-12-12 | 上海市普陀区中心医院 | Compound preparation for treating middle-low-risk pulmonary nodules, preparation method and application |
CN116920066A (en) * | 2023-09-09 | 2023-10-24 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | Traditional Chinese medicine composition for treating lung nodules and lung cancer as well as preparation and application thereof |
CN116920066B (en) * | 2023-09-09 | 2024-04-26 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | Traditional Chinese medicine composition for treating lung nodules and lung cancer as well as preparation and application thereof |
CN117244015A (en) * | 2023-09-12 | 2023-12-19 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | Traditional Chinese medicine composition for treating pulmonary nodules and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN114042124B (en) | 2022-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114042124B (en) | Traditional Chinese medicine preparation for treating pulmonary vitreous nodules and preparation method and application thereof | |
CN103520395B (en) | Traditional Chinese medicine composition for treating lung cancer | |
CN104873705A (en) | Medicinal composition for treating angina pectoris of coronary heart disease and application thereof | |
CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
CN105213941A (en) | A kind of Chinese medicine composition being used for the treatment of infantile diarrhea and preparation method thereof | |
CN111097030A (en) | Traditional Chinese medicine composition for treating tumors and relieving tumor pain and preparation method thereof | |
CN105233188A (en) | Traditional Chinese medicine composition for treating liver cancer and application of traditional Chinese medicine composition | |
CN105535495A (en) | Chinese medicinal composition for treating esophageal cancer by reinforcing vital essence and strengthening primordial qi and preparation method | |
CN104257883A (en) | Traditional Chinese medicine composition for treating leucopenia after chemotherapy | |
CN104225339A (en) | Chinese medicinal preparation for treating chronic pneumonia and preparation method | |
CN103816352B (en) | One treats colpitic Chinese medicine preparation and preparation method | |
CN105434739A (en) | Traditional Chinese medicine composition for treating chalazia and preparation method thereof | |
CN106822733B (en) | Ointment for treating precancerous lesion of chronic atrophic gastritis and preparation method thereof | |
CN1686194A (en) | Medicine for treating hemicrania and its preparation method | |
CN115252732B (en) | Traditional Chinese medicine composition for clearing lung and relieving cough and application thereof | |
CN106692821A (en) | Traditional Chinese medicine preparation for treating neurosurgical postoperative headache | |
CN104998189A (en) | Traditional Chinese medicine powder for treating infantile oral ulcer of wind-heat spleen type and preparation method thereof | |
CN105148067A (en) | Traditional Chinese medicine composition for treating tumors | |
CN104873751A (en) | Traditional Chinese medicinal decoction for treating chronic bronchitis | |
CN104606447A (en) | Traditional Chinese medicine preparation for treating exogenous fever | |
CN104721786A (en) | Traditional Chinese medicine preparation for treating intrahepatic cholestasis of pregnancy and preparation method of traditional Chinese medicine preparation | |
CN117244015A (en) | Traditional Chinese medicine composition for treating pulmonary nodules and application thereof | |
CN111773350A (en) | Traditional Chinese medicine composition for improving stomachache and rheumatic inflammation and preparation and application thereof | |
CN115282247A (en) | Traditional Chinese medicine for treating advanced cancer and preparation method thereof | |
CN110368462A (en) | Treat the Chinese medicine composition of atrophic gastritis and its preparation method of capsule |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |